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Th   e hereditary breast and ovarian cancer predisposition 
genes  BRCA1 and BRCA2 have crucial roles in the 
control of double strand break (DSB) repair by homolo-
gous recombination (HR). BRCA1 functions early in HR, 
interacting with nucleases, including CtIP and the 
Mre11/  Rad50/NBS1 (MRN) complex to coordinate DNA 
end resection to form single-stranded DNA [1]. BRCA1 
also recruits BRCA2 to the break site. BRCA2 is a key 
repair component that loads the Rad51 recombinase onto 
single-stranded DNA of the processed DSB [2-4]. DSBs 
in cycling somatic cells are thought to arise predomi-
nantly during the DNA synthesis phase of the cell cycle, 
when a replicative DNA polymerase stalls on abnormal 
DNA structure. Some models invoke the use of HR to 
repair the broken fork using the undamaged neighboring 
sister chromatid as a template [5-7]. However, not all HR 
requires a DSB intermediate; a fork-stalling DNA adduct 
may be bypassed without complete breakage (‘collapse’) 
of the fork. Because the stalled fork is structurally diﬀ  er-
ent from an isolated DSB, the mechanisms governing HR 
in these two contexts may diﬀ  er. Circumstantial evidence 
suggests that critical events underlying breast cancer 
risk, as well as the therapeutic action of poly(ADP) ribose 
polymerase inhibitors on BRCA-linked cancers, are 
played out at sites of DNA polymerase stalling [8-10]. 
Paradoxically, however, the experimental tools available 
for studying HR at sites of mammalian DNA polymerase 
stalling are quite limited.
In a paper published recently in Cell, Schlacher and 
colleagues [11] have taken an interesting new approach 
to studying how BRCA2 aﬀ  ects stalled fork metabolism. 
Th   e authors used single-molecule DNA ﬁ  ber analysis to 
determine the fate of newly synthesized (‘nascent’) DNA 
strands just proximal to replication forks in cells treated 
with hydroxyurea (HU), an agent that depletes the 
nucleotide pool, causing genome-wide DNA polymerase 
stalling. In wild-type cells, the nascent strands at HU-
arrested forks were protected from degradation. In 
contrast, cells lacking wild-type BRCA2 revealed progres-
sive erosion of nascent DNA strands. Th   e authors identi-
ﬁ   ed the DNA end resection complex MRN as a key 
mediator of this process. Precisely what DNA structures 
MRN acts on to erode the nascent strands at HU-arrested 
forks in BRCA2 mutants is not yet clear, although it likely 
involves MRN-mediated resection of a DNA end. In 
wild-type cells, the short period of exposure to HU 
described by Schlacher and colleagues should produce 
few if any DSBs as direct products of fork collapse [12]. In 
this regard, one previous report suggested that BRCA2
mutant cells are particularly susceptible to replication 
fork collapse following prolonged HU treatment [13]. 
Th  is raises the possibility that MRN acts on DNA ends 
produced by fork collapse in BRCA2 mutants. If this were 
the case, however, only a fraction of all nascent strands 
should show the observed resection. Th  e fact that 
Schlacher and colleagues observed coordinated resection 
of all nascent strands, a process that had evidently begun 
within minutes of HU exposure, suggests that a mecha-
nism other than fork collapse generated the DNA ends 
that MRN attacks. Experiments in yeast and bacteria 
have revealed that stalled forks can undergo ‘fork 
reversal’ - a process whereby the fork backtracks on its 
path, generating a cruciform DNA structure called a 
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The hereditary breast and ovarian cancer predisposition 
genes BRCA1 and BRCA2 account for the lion’s share of 
heritable breast cancer risk in the human population. 
Loss of function of either gene results in defective 
homologous recombination (HR) and triggers genomic 
instability, accelerating breast tumorigenesis. A long-
standing hypothesis proposes that BRCA1 and BRCA2 
mediate HR following attempted replication across 
damaged DNA, ensuring error-free processing of the 
stalled replication fork. A recent paper describes a new 
replication fork protective function of BRCA2, which 
appears to collaborate with its HR function to suppress 
genomic instability.
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© 2011 BioMed Central Ltd‘chicken foot’, with a single exposed DNA end composed 
of paired nascent strands [14,15]. Schlacher and colleagues 
speculate that an equivalent structure can form in 
mammalian cells and that BRCA2 either prevents its 
formation or helps to protect the free DNA end of this 
cruciform structure from attack by MRN.
BRCA2 protection of the HU-stalled fork from MRN-
mediated resection could reﬂ  ect a non-canonical role for 
BRCA2/Rad51 at stalled forks. Indeed, Schlacher and 
colleagues found that a BRCA2 mutant lacking the 
carboxy-terminal Rad51 binding domain is defective for 
protection against HU-triggered nascent strand 
resection, but retains intact HR repair of a chromosomal 
DSB. Th  ese observations, together with other experi-
ments reported in the paper, suggest that BRCA2 has a 
‘stalled fork-protective’ function mediated by its stabiliz-
ing eﬀ   ect on the Rad51 nucleoprotein ﬁ  lament  but 
distinct from its role in traditional DSB repair by HR [11]. 
A caveat of this interpretation is the likelihood that HR at 
stalled forks involves mechanisms additional to those 
required for HR at an isolated DSB. Perhaps the ‘fork-
protective’ function of BRCA2 is indeed required for HR 
at stalled forks, but not for HR at isolated DSBs. Data 
obtained with use of HU also pose some problems of 
interpretation, since HU produces genome-wide arrest of 
otherwise structurally normal replication forks. It is not 
clear to what extent this static form of ‘replication stress’ 
reﬂ  ects the dynamic interactions that occur between the 
replication fork and a DNA polymerase-stalling carcino-
genic DNA adduct.
Our current view of BRCA1 and BRCA2 suggests that 
regulation of HR at stalled replication forks inﬂ  uences 
the probability of a woman developing breast cancer as 
well as her response to therapy. Th  e work by Schlacher 
and colleagues reveals new mechanisms underlying this 
relationship. Th  e rewards of continuing to dig deeper 
into basic mechanisms of action of the BRCA genes will 
be a better understanding of breast cancer risk and breast 
cancer therapy. Perhaps this will include the discovery of 
new therapies that take advantage of the replication-
recombination ‘Achilles heel’ of BRCA mutant breast 
cancers and of other cancers in which HR is defective.
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